Assessing the evidence–practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics
Open Access
- 9 December 2019
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 22 (4), 646-660
- https://doi.org/10.1002/ejhf.1630
Abstract
Background Registry studies in high‐income countries have defined contemporary management of heart failure (HF), but few such data exist in the large aging population of China. We report the study design and baseline characteristics of the Heart Failure Registry of Patient Outcomes (HERO) study, undertaken to determine evidence–practice gaps in the management of HF in a broad and representative population of China. Methods and results The HERO study is a prospective, longitudinal, seasonally‐rotating, multicentre registry study of patients hospitalized with acute HF who are followed up over 12 months. Patients were recruited on the basis of primary admission clinical diagnosis of acute HF at 73 hospitals in Henan, the largest and most socio‐economically diverse province in China, from November 2017 to November 2018; follow‐up is ongoing. For each patient, data obtained through interview and medial record review by independent clinical research staff include: socio‐demographics, clinical features, diagnostic investigations, and treatment, with a subset of patients providing blood samples for future biomarker investigation. Surviving patients are scheduled to be followed up by telephone at 2 weeks, and 3, 6 and 12 months post‐admission, or until death or study withdrawal. A total of 5620 patients (mean age 72 ± 12 years; 50% female) with acute HF were recruited from 8 provincial‐, 22 municipal‐, and 43 county‐level hospitals. Patients had co‐morbid hypertensive (48%), coronary (29%), or metabolic (20%) diseases. Among 3147 patients who had echocardiography, 54%, 20% and 25% of patients had ejection fraction of ≥50%, 40–50%, and < 40%, respectively. In‐hospital or 3‐day post‐discharge mortality was 3.2% (182/5620). Death or readmission rate from the 4th day post‐discharge to first follow‐up (median 32 days) was 22.4% (977/4368). Conclusions The HERO study provides a unique opportunity to profile evidence–practice gaps across a broad spectrum of patients with acute HF in China.Keywords
This publication has 35 references indexed in Scilit:
- Recent National Trends in Readmission Rates After Heart Failure HospitalizationCirculation: Heart Failure, 2010
- A Validated Risk Score for In-Hospital Mortality in Patients With Heart Failure From the American Heart Association Get With the Guidelines ProgramCirculation: Cardiovascular Quality and Outcomes, 2009
- An Update on the Self-care of Heart Failure IndexJournal of Cardiovascular Nursing, 2009
- Predictors of In-Hospital Mortality in Patients Hospitalized for Heart FailureJournal of the American College of Cardiology, 2008
- EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of populationEuropean Heart Journal, 2006
- ACC/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Chronic Heart FailureCirculation, 2005
- Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)American Heart Journal, 2005
- Trends in Heart Failure Incidence and Survival in a Community-Based PopulationJAMA, 2004
- Seasonal congestive heart failure mortality and hospitalisation trends, Quebec 1990-1998Journal of Epidemiology and Community Health, 2004
- The PHQ-9Journal of General Internal Medicine, 2001